A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women

European Journal of Preventive Cardiology

Volumn 10, Issue 2, 2003, Pages 129-135

  Tonstad, Serena ^a   Hjermann, Ingvar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

blood pressure; coronary heart disease; high density lipoprotein cholesterol; metabolic syndrome; screening; triglycerides

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDUCATION; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE; AGE; ANGINA PECTORIS; ASIAN; DIET THERAPY; FAMILIAL DISEASE; FOLLOW UP; HYPERCHOLESTEROLEMIA; MASS SCREENING; NORWAY; RISK ASSESSMENT;

EID: 0037396597     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/174182670301000208     Document Type: Article

References (22)

1. Task Force Report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434–1503.
2. Tonstad S. Should we only consider absolute risk when treating risk factors for cardiovascular disease? J Nor Med Assoc 1998; 118: 2966–2968.
3. Expert Panel on Detection, evaluation, and treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486–2497.
4. Tonstad S, Hjermann I. Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial. J Intern Med 2000; 248: 111–118.
5. Westlund K, Nicolaysen R. Ten-year mortality and morbidity related to serum cholesterol. A follow-up of 3751 men aged 40–49. Scand J Clin & Lab Invest 1972; suppl 127: 1–24.
6. Juo S-HH, Beaty TH, Kwiterovich PO Jr. Etiologic heterogeneity of hyperapobetalipoproteinemia (hyperapo β). Arterioscler Thromb Vasc Biol 1997; 17: 2729–2736.
7. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–362.
8. Jenum AK, Stensvold I, Bjartveit K, Thelle DS, Hjermann I. Cardiovascular risk factors in Oslo, 1981–88. J Nor Med Assoc 1998; 118: 18–22.
9. Karlsen KB, Graff-Iversen S, Knapskog A-B. Criteria of general practitioners on the high risk factors for cardiovascular diseases. Information from health survey cards of 40-year-old persons in Telemark. J Nor Med Assoc 1994; 114: 3427–3430.
10. Holmen J, Midthjell K, Forsen L, Skjerve K, Gorseth M, Oseland A. A health survey in Nord-Trondelag 1984–86. Participation and comparison of attendants and non-attendants. J Nor Med Assoc 1990; 110: 1973–1977.
11. Rosengren A, Wilhelmsen L, Berglund G, Elmfeldt D. Non-participants in a general population study of men, with special reference to social and alcoholic problems. Acta Med Scand 1987; 221: 243–251.
12. Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT, et al The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 328: 1213–1219.
13. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1114–1120.
14. Patmore J, Coyle S, Jones R, Wieringa G. Hypercholesterolaemia: Not all cases warrant treatment. BMJ 1993; 307: 1125–1126.
15. Durrington PN, Prais H. Methods for the prediction of coronary heart disease risk. Heart 2001; 85: 489–490.
16. Silva JM, Silva PS. Sexless HDL. Lancet 1994; 343: 129–130.
17. Sniderman AD, Dagenais GR, Cantin B, Després J-P, Lamarche B. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am J Cardiol 2001; 87: 792–793.
18. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477–484.
19. Dotevall A, Rosengren A, Lappas G, Wilhelmsen L. Does immigration contribute to decreasing CHD incidence? Coronary risk factors among immigrants in Göteborg, Sweden. J Intern Med 2000; 247: 331–339.
20. Lampe FC, Whincup PH, Wannamethee SG, Ebrahim S, Walker M, Shaper AG. Chest pain on questionnaire and prediction of major ischaemic heart disease events in men. Eur Heart J 1998; 19: 63–73.
21. Wilhelmsen L, Rosengren A, Harman M, Lappas G. ‘Non-specific’ chest pain associated with high long-term mortality: Results from the Primary prevention Study in Göteborg, Sweden. Clin Cardiol 1998; 21: 477–482.
22. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.